icon-folder.gif   Conference Reports for NATAP  
 
  EASL 47th Annual Meeting
April 18th - 22nd 2012
Barcelona, Spain
Back grey_arrow_rt.gif
 
 
 
ABT-450/ritonavir (ABT-450/r) Combined With Pegylated Interferon Alpha-2a/Ribavirin (P/R) After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Na´ve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results
 
 
  Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
 
Eric Lawitz1, Fred Poordad2, Edwin DeJesus3, Kris V Kowdley4, Isabelle Gaultier5, Daniel Cohen5, Wangang Xie5, Lois Larsen5, Tami Pilot-Matias5, Rajeev M Menon5, Thomas Podsadecki5, Barry Bernstein5
1Alamo Medical Research, San Antonio, Texas, United States; 2Cedars-Sinai Medical Center, Los Angeles, California, United States; 3Orlando Clinical Research Center, Orlando, Florida, United States; 4Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States; 5Abbott, Abbott Park, Illinois, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif

EASL9.gif

EASL10.gif

EASL11.gif

EASL12.gif

EASL13.gif